AdhexPharma in the news

AdhexPharma's R&D center, Labtec, is constructing a toxicology laboratory and cleanroom to enhance its capacity for handling potent pharmaceutical compounds and manufacturing clinical batches.

Adhex Pharma is expanding its industrial site in Chenôve to relocate the production of essential painkiller patches from Germany to France.

AdhexPharma is localizing the production of strategic medicines and health products at its facility near Dijon.

French officials visited AdhexPharma in Chenôve to mark the successful relocation of 42 strategic medical products for domestic production.

AdhexPharma is investing 25 million euros in a new 8,000 square meter production facility near Dijon to relocate manufacturing from Germany.

AdhexPharma is investing 25 million euros to relocate production from its German subsidiary to France and plans to hire 50 new employees in Chenôve.

Adhex Pharma is investing 25.1 million euros to relocate drug production from Germany to a new 8,000 square meter facility in Dijon.

A 25 million euro investment at the Chenôve facility will relocate pharmaceutical patch production from Germany to France and create 50 new jobs.

AdhexPharma is relocating the production of 42 strategic medicines to its facility near Dijon to strengthen French industrial sovereignty.

Sébastien Martin applauded Adhex Pharma's re-industrialization efforts, noting the repatriation of 42 strategic health products and medicines, with Adhex Pharma's Chenôve site producing one of them.

AdhexPharma has repatriated 42 strategic medicines to its Chenôve site to strengthen French industrial sovereignty in the health sector.

AdhexPharma is relocating its German production activities to France through a major industrial investment supported by the France 2030 plan.

Minister of Industry Sébastien Martin will visit Adhex Pharma to support their France 2030 project of relocating medicated patch production from Germany to France.

AdhexPharma is relocating its German subsidiary's drug delivery manufacturing to France under the France 2030 industrial sovereignty plan.

Adhex will create 60 jobs in Chenôve by 2026, actively recruiting new profiles.

Adhex group invested €25 million in a new building and expanded through acquisition, focusing on adhesive solutions and drug delivery technologies with significant R&D and hiring plans.

Adhex Pharma is expanding its Chenôve production site with a €25 million investment, creating 60 jobs and relocating some production from Germany to France.

AdhexPharma is investing 25 million euros to expand its Chenôve facility, reshore German production, and hire 60 new staff members.

AdhexPharma is expanding its Dijon facility to integrate production from its German subsidiary Labtec, repatriating patch manufacturing by 2026.

The French government is funding seven pharmaceutical projects, including a new energy-efficient factory for AdhexPharma, to enhance drug production and supply security.